<DOC>
	<DOCNO>NCT02259426</DOCNO>
	<brief_summary>Primaquine ( PQ ) currently available drug clear mature transmission stage P. falciparum parasite . PQ previously show clear gametocyte persist artemisinin-combination therapy . A major caveat use primaquine mass adminsitrations reduction malaria transmission metabolism drug individual glucose-6 phosphate dehydrogenase ( G6PD ) deficiency lead transient haemolysis . The haemolytic side effect PQ dose-related . Haemolysis commonly observe prolonged PQ treatment also observe African population follow single dose PQ . This haemolysis self-limiting , largely restrict G6PD deficient individual lead clinical symptom . Nevertheless , drug-induced haemolysis reason concern World Health Organization therefore reduce recommend dose single low dose primaquine 0.75mg/kg 0.25mg/kg . This dosage deem safe without prior G6PD Hb screening . However , limited direct evidence extent dosage PQ prevent malaria transmission mosquito . In current study , investigator assess efficacy DP combination low-dose PQ prevent onward malaria transmission . The investigator perform investigator study individual age 5-15 year carry microscopically detectable density P. falciparum gametocyte . This age group choose asexual parasite carriage gametocyte carriage common age group . All enrolled individual receive full three-day course DP , randomize receive dose primaquine placebo third dose . Efficacy determine base gametocyte carriage follow-up , measure molecular method . For individual , effect treatment infectivity mosquito assess membrane feed assay two time point .</brief_summary>
	<brief_title>Dihydroartemisinin-piperaquine With Low Dose Primaquine Reduce Malaria Transmission</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Microscopically detectable P. falciparum gametocyte carriage Age &lt; 5 year &gt; 15 year Nonfalciparum malaria coinfection Malaria parasite density ≥ 200,000 parasites/µL Clinical symptom indicate severe malaria Axillary temperature ≥ 39°C Body Mass Index ( BMI ) 16 32 kg/m2 Haemoglobin concentration 9.5 g/dL Antimalarials take last 2 day For woman : Pregnancy ( assessed clinical examination urine pregnancy test ) lactation Known hypersensitivity DP PQ History and/or symptom indicate chronic illness Current use tuberculosis antiretroviral medication Unable give write informed consent Unwillingness participate two membrane feed assay Travel history Angola , Cameroon , Chad , Central African Republic , Congo , DR Congo , Equatorial Guinea , Ethiopia , Gabon , Nigeria Sudan Family history congenital prolongation QTc interval sudden death clinical condition know prolong QTc interval history symptomatic cardiac arrhythmia , clinically relevant bradycardia severe cardiac disease Taking drug know influence cardiac function prolong QTc interval , class IA III : neuroleptic , antidepressant agent , certain antibiotic include agent follow class macrolides , fluoroquinolones , imidazole , triazole antifungal agent , certain nonsedating antihistaminics ( terfenadine , astemizole ) cisapride Known disturbance electrolyte balance , e.g . hypokalaemia hypomagnesaemia Taking drug may metabolize cytochrome enzyme CYP2D6 ( e.g. , flecainide , metoprolol , imipramine , amitriptyline , clomipramine ) Blood transfusion within last 90 day</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>